These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 15604285)

  • 1. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
    Malathi K; Paranjape JM; Ganapathi R; Silverman RH
    Cancer Res; 2004 Dec; 64(24):9144-51. PubMed ID: 15604285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
    Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
    Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates.
    Xiang Y; Wang Z; Murakami J; Plummer S; Klein EA; Carpten JD; Trent JM; Isaacs WB; Casey G; Silverman RH
    Cancer Res; 2003 Oct; 63(20):6795-801. PubMed ID: 14583476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L.
    Malathi K; Paranjape JM; Bulanova E; Shim M; Guenther-Johnson JM; Faber PW; Eling TE; Williams BR; Silverman RH
    Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14533-8. PubMed ID: 16203993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
    Perego P; Ciusani E; Gatti L; Carenini N; Corna E; Zunino F
    Biochem Pharmacol; 2006 Mar; 71(6):791-8. PubMed ID: 16438941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
    Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential role of c-Jun-NH2-terminal kinase on synergy induction of apoptosis by TRAIL plus ADM in ADM resistant MCF-7/ADM cells.
    Li F; Meng L; Xing H; Zhou J; Wang S; Huang L; Xu G; Zhu H; Lu Y; Ma D
    Apoptosis; 2006 Jul; 11(7):1239-46. PubMed ID: 16703262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T; Sugamura K; Hylander BL; Widmer MB; Rustum YM; Repasky EA
    Cancer Res; 2002 Oct; 62(20):5800-6. PubMed ID: 12384541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
    Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
    Griffith TS; Kemp TJ
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):175-84. PubMed ID: 12811515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
    Lakshmikanthan V; Kaddour-Djebbar I; Lewis RW; Kumar MV
    Int J Cancer; 2006 Jul; 119(1):221-8. PubMed ID: 16450389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK; VanOosten RL; Griffith TS
    Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase.
    Sah NK; Munshi A; Kurland JF; McDonnell TJ; Su B; Meyn RE
    J Biol Chem; 2003 Jun; 278(23):20593-602. PubMed ID: 12663665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Methoxy-canthin-6-one induces c-Jun NH2-terminal kinase-dependent apoptosis and synergizes with tumor necrosis factor-related apoptosis-inducing ligand activity in human neoplastic cells of hematopoietic or endodermal origin.
    Ammirante M; Di Giacomo R; De Martino L; Rosati A; Festa M; Gentilella A; Pascale MC; Belisario MA; Leone A; Turco MC; De Feo V
    Cancer Res; 2006 Apr; 66(8):4385-93. PubMed ID: 16618764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells.
    Wang G; Ahmad KA; Ahmed K
    Cancer Res; 2006 Feb; 66(4):2242-9. PubMed ID: 16489027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines.
    Mikami T; Koyama T; Koyama T; Imakiire A; Yamamoto K; Furuhata M; Toyota H; Mizuguchi J
    Anticancer Res; 2006; 26(2A):1153-60. PubMed ID: 16619517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells.
    Zou W; Liu X; Yue P; Zhou Z; Sporn MB; Lotan R; Khuri FR; Sun SY
    Cancer Res; 2004 Oct; 64(20):7570-8. PubMed ID: 15492284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.